Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 28, 2020
- Accepted July 18, 2020
- Published online September 9, 2020.
Article Versions
- previous version (August 27, 2020 - 05:00).
- You are currently viewing a previous version of this article (September 9, 2020 - 16:05).
- View the most recent version of this article
Copyright & Usage
Copyright ©ERS 2020
Author Information
- Michael R. Loebinger1,2,
- Eva Polverino3,
- James D. Chalmers4,
- Harm A.W.M. Tiddens5,6,
- Herman Goossens7,
- Michael Tunney8⇑,
- Felix C. Ringshausen9,
- Adam T. Hill10,
- Rashidkhan Pathan11,
- Gerhild Angyalosi12,
- Francesco Blasi13,14,
- Stuart J. Elborn2,15,16 and
- Charles S. Haworth17,18
- on behalf of the iBEST-1 Trial Team
- 1Host Defence Unit, Royal Brompton Hospital and Harefield NHS Foundation Trust, London, UK
- 2Imperial College London, London, UK
- 3Respiratory Disease Department, Vall d’ Hebron University Hospital – VHIR, Barcelona, Spain
- 4Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, UK
- 5Department of Paediatric Pulmonology and Allergology, Erasmus Medical Centre Sophia Children's Hospital, Rotterdam, The Netherlands
- 6Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
- 7Department of Clinical Microbiology, University Hospital Antwerp, Antwerp, Belgium
- 8Halo Research Group, School of Pharmacy, Queen's University Belfast, Belfast, UK
- 9Department of Respiratory Medicine, Hannover Medical School, and Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany
- 10Department of Respiratory Medicine, Royal Infirmary of Edinburgh, and University of Edinburgh, Edinburgh, UK
- 11Novartis Healthcare Private Limited, Hyderabad, India
- 12Novartis Pharma AG, Basel, Switzerland
- 13Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
- 14Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
- 15Halo Research Group, Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK
- 16Imperial College and Royal Brompton Hospital and Harefield NHS Foundation Trust, London, UK
- 17Cambridge Centre for Lung Infection, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK
- 18Department of Medicine, University of Cambridge, Cambridge, UK
- Dr Michael R Loebinger, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom. E-mail: M.Loebinger{at}rbht.nhs.uk
Funding
Novartis Foundation
Innovative Medicines Initiative
Inhaled Antibiotics in Bronchiectasis and Cystic F
Article usage
Altmetrics
Vol 57 Issue 4
Table of Contents
Efficacy and safety of TOBI Podhaler® in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study
